396 related articles for article (PubMed ID: 25086990)
41. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
42. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
Rudloff U; Langan RC; Mullinax JE; Beane JD; Steinberg SM; Beresnev T; Webb CC; Walker M; Toomey MA; Schrump D; Pandalai P; Stojadinovic A; Avital I
J Surg Oncol; 2014 Sep; 110(3):275-84. PubMed ID: 25042700
[TBL] [Abstract][Full Text] [Related]
43. [Surgical Management of Peritoneal Surface Malignancy with Respect to Tumour Type, Tumour Stage and Individual Tumour Biology].
Beckert S; Struller F; Grischke EM; Glatzle J; Zieker D; Königsrainer A; Königsrainer I
Zentralbl Chir; 2016 Aug; 141(4):415-20. PubMed ID: 24241953
[TBL] [Abstract][Full Text] [Related]
44. Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?
Baratti D; Kusamura S; Iusco D; Cotsoglou C; Guaglio M; Battaglia L; Virzì S; Mazzaferro V; Deraco M
Dis Colon Rectum; 2018 Sep; 61(9):1026-1034. PubMed ID: 30086051
[TBL] [Abstract][Full Text] [Related]
45. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
46. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
47. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.
Frøysnes IS; Larsen SG; Spasojevic M; Dueland S; Flatmark K
J Surg Oncol; 2016 Aug; 114(2):222-7. PubMed ID: 27173150
[TBL] [Abstract][Full Text] [Related]
48. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach?
Sugarbaker PH; Ryan DP
Lancet Oncol; 2012 Aug; 13(8):e362-9. PubMed ID: 22846841
[TBL] [Abstract][Full Text] [Related]
49. Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
Kecmanovic DM; Pavlov MJ; Ceranic MS; Sepetkovski AV; Kovacevic PA; Stamenkovic AB
Eur J Surg Oncol; 2005 Mar; 31(2):147-52. PubMed ID: 15698730
[TBL] [Abstract][Full Text] [Related]
50. Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Devilee RA; Simkens GA; van Oudheusden TR; Rutten HJ; Creemers GJ; Ten Tije AJ; de Hingh IH
Ann Surg Oncol; 2016 Sep; 23(9):2841-8. PubMed ID: 27044447
[TBL] [Abstract][Full Text] [Related]
51. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.
Cashin PH; Graf W; Nygren P; Mahteme H
Eur J Surg Oncol; 2012 Jun; 38(6):509-15. PubMed ID: 22475555
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
53. Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases.
Hentzen JEKR; van der Plas WY; Kuipers H; Ramcharan S; Been LB; Hoogwater FJH; van Ginkel RJ; van Dam GM; Hemmer PHJ; Kruijff S
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):590-599. PubMed ID: 31806520
[TBL] [Abstract][Full Text] [Related]
54. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
55. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.
Golse N; Bakrin N; Passot G; Mohamed F; Vaudoyer D; Gilly FN; Glehen O; Cotte E
J Surg Oncol; 2012 Aug; 106(2):197-203. PubMed ID: 22331814
[TBL] [Abstract][Full Text] [Related]
56. Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
van Eden WJ; Kok NF; Jóźwiak K; Lahaye ML; Beets GL; van Leerdam ME; Boot H; Aalbers AG
Dis Colon Rectum; 2017 May; 60(5):477-487. PubMed ID: 28383447
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
[TBL] [Abstract][Full Text] [Related]
58. Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy.
Klaver YL; de Hingh IH; Boot H; Verwaal VJ
J Surg Oncol; 2011 Apr; 103(5):431-4. PubMed ID: 21400529
[TBL] [Abstract][Full Text] [Related]
59. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
60. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
